13G Filing: Jim Tananbaum’s Foresite Capital Buys More Shares of Aerie Pharmaceuticals Inc (AERI)

Page 8 of 11

Page 8 of 11 SEC Filing

(a) Amount beneficially owned:

See Row 9 of cover page for each Reporting
Person.

(b) Percent of Class:

See Row 11 of cover page for each
Reporting Person.

(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting
Person.

(ii) Shared power to vote or to direct the vote:

See Row 6 of cover page for each
Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each
Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each
Reporting Person.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON
.
Under certain circumstances set forth in the limited partnership agreements of FCF II and FCF III and the limited liability
company agreements of FCM II and FCM III the partners or members, as the case may be, of each of such entities may be deemed to
have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by
each such entity of which they are a partner or member.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE
GROUP
.
Not applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable
ITEM 10. CERTIFICATION.
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and
were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other
than activities solely in connection with a nomination under § 240.14a-11.

Follow Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Page 8 of 11